Levitra

All Rights Reserved.

This material may not be published, broadcast, rewritten, or redistributed.

Back To Top AdvertisementBUSINESS VIDEOSFord Fusion Poor In Crash Test E-MailMore Video Adv...

Wenning said Bayer wants to widen its health care unit and would consider making acquisitions to expand its over-the-counter drug lineup - providing that targets fit Bayer's business plan.

Wenning made the remark at a news conference when asked whether Bayer would bid for Pfizer's over-the-counter division, if it were put up for sale.

Pfizer said last month it might sell or spin off the unit.

Bayer's crop science division had a slight decline in sales of less than 1 percent to euro5.89 billion (US$7.07 billion) while its MaterialScience unit, which produces and sells plastics, reported growth of 24.4 percent to euro10.69 billion (US$12.8 billion) in 2005.

Shares of Bayer were down nearly 3.8 percent to euro32.52 (US$39.08) in Frankfurt trading.

- On the Net: http://www.bayer.com Copyright 2005, by The Associated Press.

All rights reserved.

This material may not be published, broadcast, rewritten or redistributed.

BW MALL SPONSORED LINKS Hot Stock Picks for Tomorrow Free report covering hot stock picks & tips, penny stocks, new issues, undervalued & undiscovered situations, and other aggressive stock ideas.

E-LOAN ® - Official Site Low Rate Mortgage, Home Equity, and Auto Loans.

Approval in Minutes.

No Lender fe...

'This drug still has blockbuster potential,' Plischke said.

As for the kidney cancer drug Nexavar, which was launched in the US recently, Plischke said he still expects approval in the European Union in the second half this year.

Media reports have suggested the company expects the drug to post sales around 30 mln eur this year, but Plischke said: 'It will be significantly above that,' although he said it would not run to three digits.

Bayer currently has eight pharmaceutical products in phase III clinical development and three projects in phase II.

Finally, there are twelve projects in phase I and another eleven in pre-clinical development.

However, Plischke said Bayer is always on the lookout for drugs to license in.

'We are working intensively to license in new products,' he said, although he would not be more specific as to when this will happen.

ragnhild.kjetland@afxnews.com rkj/jsa COPYRIGHT Copyright AFX News Limited 2005.

All rights reserved.

The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.

AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited Neither the Subscriber nor AFX News warrants the completeness or accuracy of the Service...